Abbott Laboratories (ABT)
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential
Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.
How Abbott's Largest Segment Is Preparing for the Next Growth Phase
ABT's Medical Devices unit builds on strong growth with new diabetes, heart rhythm and electrophysiology advances ahead of Q2 2026.
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
Abbott Laboratories (NYSE:ABT | ABT Price Prediction) at $90.53 is a Buy.
MiniMed Launches Abbott's Instinct Sensors Across European Markets
MMED expands its European diabetes tech reach with Abbott sensor integration, boosting user flexibility and its connected care ecosystem.
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test
ALZpath said on Wednesday it had signed a global licensing agreement with Abbott Laboratories to help advance blood-based testing for Alzheimer's disease, as companies race to offer easier-to-use diagnostic options for the brain-wasting disease.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation
ABT's CGM sales growth slows in Q1, but management sees a return to double-digit gains as Libre expands with new products and AI tools.
Abbott (ABT) Stock Declines While Market Improves: Some Information for Investors
Abbott (ABT) closed the most recent trading day at $88.18, moving 1.64% from the previous trading session.
Abbott Laboratories Remains Structurally Undervalued
Abbott Laboratories is rated a strong buy due to structural undervaluation and resilient fundamentals despite recent negative price action. ABT trades at a 17.1% P/E and 35.1% sales multiple discount to peers, with DCF fair value estimates implying 21.8–39.4% upside. Growth is underpinned by the Exact Sciences acquisition, diagnostics megatrends, and global expansion in CGM, with FY26 guidance raised for both sales and EPS.
